IL37 and neoplasm: IL-37 in addition to alone was sufficient to cause a decrease in motive and migratory capacity of PDAC cells, it could sensitize and improve the efficacy of Gemcitabine that acted as the standard treatment for PDAC both in vivo and in vitro through IL-37/STAT3/HIF-1α pathway, thereby reversing the resistance in most of the treated patients and further exerting the inhibitory effect in tumor progression (115).